Skip to main content

Financial News

  • Cardinal Health year-end revenues up 19% to $121.5 billion

    DUBLIN, Ohio - Cardinal Health on Tuesday closed out its fiscal year 2016 on quarterly revenues of $31.4 billion, representing an increase of 14%. For the year, Cardinal Health posted revenues of $121.5 billion, an increase of 19%.

  • Mass market still most shopped channel

    More vitamins, minerals and supplements were sold online so far in 2016 than have been sold through a Walmart store, TABS Analytics reported earlier this year. According to the TABS Analytics analysis, $2 billion in VMS products were sold online vs. $1.7 billion at Walmart, $1.3 billion at Costco and $1.2 billion at CVS Pharmacy.

  • With Rite Aid deal on track, Walgreens Boots Alliance posts Q3 sales of $29.5 billion, up 2.4%

    DEERFIELD, Ill. — Walgreens Boots Alliance on Wednesday reported an adjusted net earnings increase of 14.7% to $1.3 billion for its third quarter ended May 31. Net sales in the third quarter were $29.5 billion, an increase of 2.4% over the year-ago quarter, or 3.3% on a constant currency basis.

    Walgreens Boots Alliance's Retail Pharmacy USA division had third quarter total sales of $21.2 billion, an increase of 3.7% over the year-ago quarter. Sales in comparable stores increased 3.9% compared to the same quarter a year ago.

  • Jean Coutu sees generics slow Q1 Rx retail sales growth
    VARENNES, Quebec — Canada’s Jean Coutu group on Tuesday released the sales and earnings figures from its FY2017 first quarter, which ended May 28. For the quarter, the company saw revenues of $723.6 million — a 1.6% rise over the same quarter last year. The company attributes its sales growth to overall market growth and the expansion of its franchised store network. 
     

  • Kroger Q1 ID sales up 2.4%

    CINCINNATI - Kroger on Thursday reported net earnings of $680 million, or $0.70 per diluted share, and identical supermarket sales growth, without fuel, of 2.4% in the first quarter of 2016. Kroger's net earnings during the first quarter last year were $619 million, or $0.62 per diluted share.

  • Rite Aid posts 23.1% Q1 revenue gain to $8.2 billion

    CAMP HILL, Pa. - Rite Aid on Thursday reported revenues of $8.2 billion, a net earnings loss of $4.6 million, or $0.00 per diluted share, adjusted net income of $14.5 million, or $0.01 per diluted share and adjusted EBITDA of $286 million, or 3.5% of revenues for its first fiscal quarter ended May 28, 2016.

  • Merck to acquire Afferent Pharmaceuticals
    KENILWORTH, N.J. and SAN MATEO, Calif. — Merck announced Thursday that it would be acquiring the privately held Afferent Pharmaceuticals. Afferent is a leader in developing therapeutic candidates to treat common, poorly managed neurogenic conditions by targeting the P2X3 receptor, and its lead candidate, AF-219, is currently being evaluated in clinical trials to treat refractory, chronic cough, as well as idiopathic pulmonary fibrosis with cough. 
     

  • Sales down as focus shifts to weight management

    It’s been a little more than a year since GlaxoSmithKline Consumer Healthcare announced the return of Alli (orlistat 60 mg capsules) to most stores in the United States and Puerto Rico. Today, the over-the-counter diet aid has reclaimed much of its lost dollar base and its No. 2 spot on the list of best-selling diet aids across total U.S. multi-outlets with $30.8 million in sales for the 52 weeks ended April 17.

X
This ad will auto-close in 10 seconds